Targeting the vulnerability of arachidonic acid metabolism to enhance immunotherapy efficacy in ARID1A-deficient colorectal cancer [RNA-Seq]
RNA-seq (gene expression) · mouse · 16 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 16 samples: 5 × CT26, ARID1AknockoutIgG vs 5 × CT26, ARID1AknockoutPD1 vs 3 × CT26, ARID1Awildtype vs 3 × CT26, ARID1AknockoutGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE278083_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1165659 and SRA study SRP534943. Searching any of these in the dataset finder brings you back here.
Supports a case/control comparison: 13 samples read as cases, 3 as controls.
How we read this: 4 replicated groups read from 16 sample titles; they account for 16 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8539370 CT26, ARID1Awildtype1 CT26, ARID1Awildtype
- GSM8539371 CT26, ARID1Awildtype2 CT26, ARID1Awildtype
- GSM8539372 CT26, ARID1Awildtype3 CT26, ARID1Awildtype
- GSM8539373 CT26, ARID1Aknockout1 CT26, ARID1Aknockout
- GSM8539374 CT26, ARID1Aknockout2 CT26, ARID1Aknockout
- GSM8539375 CT26, ARID1Aknockout3 CT26, ARID1Aknockout
- GSM8539376 CT26, ARID1AknockoutIgG1 CT26, ARID1AknockoutIgG
- GSM8539377 CT26, ARID1AknockoutIgG2 CT26, ARID1AknockoutIgG
- GSM8539378 CT26, ARID1AknockoutIgG3 CT26, ARID1AknockoutIgG
- GSM8539379 CT26, ARID1AknockoutIgG4 CT26, ARID1AknockoutIgG
- GSM8539380 CT26, ARID1AknockoutIgG5 CT26, ARID1AknockoutIgG
- GSM8539381 CT26, ARID1AknockoutPD1_1 CT26, ARID1AknockoutPD1
- GSM8539382 CT26, ARID1AknockoutPD1_2 CT26, ARID1AknockoutPD1
- GSM8539383 CT26, ARID1AknockoutPD1_3 CT26, ARID1AknockoutPD1
- GSM8539384 CT26, ARID1AknockoutPD1_4 CT26, ARID1AknockoutPD1
- GSM8539385 CT26, ARID1AknockoutPD1_5 CT26, ARID1AknockoutPD1
- GSE300887 Sequential Platinum and PARP Inhibition Enhances PD1 Immunotherapy Efficacy in Murine Brca2 Mutated Pancreatic Cancer [RNAseq_1] 13 samples shares immunotherapy, efficacy, enhance
- GSE262305 Bortezomib increases immunotherapy efficacy through enhancement of STING and IFN-γ signaling in lung adenocarcinoma 9 samples shares immunotherapy, efficacy, enhance
- GSE223323 Enterocyte like differentiation defines metabolic gene signatures of CMS3 colorectal cancers and provides therapeutic vulnerability 148 samples shares vulnerability, colorectal
- GSE244034 Tumor-targeting oncolytic viruses engineered for glioblastoma immunotherapy 48 samples shares immunotherapy, targeting
- GSE281467 Coactivation of innate immune suppressive cells induces acquired resistance against cancer immunotherapy targeting the innate immune system [TIICs RNA-seq] 30 samples shares immunotherapy, targeting
- GSE330229 Accelerated RNA polymerase II elongation drives endothelial transition and plaque vulnerability: pharmacological targeting of the super elongation complex [RNA-seq] 24 samples shares vulnerability, targeting
- GSE315303 Pygo2 Loss Induces Tertiary Lymphoid Structure Formation and Enhances Immunotherapy and Castration Responses in Prostate Cancer 22 samples shares immunotherapy, enhance
- GSE263625 Microglial reprogramming enhances antitumor immunity and immunotherapy response in melanoma brain metastases 19 samples shares immunotherapy, enhance
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.